Skip to main content

Table 4 Characteristics of Phase 2 patients who had objective responses after treatment with IL-21 plus sorafenib

From: Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

Subject Best response (Independent assessment) Site(s) of disease Prior therapy(ies)
1021 PR Liver, LNs Sunitinib, Temsirolimus
1027 PR Lung, LNs, pancreas, bone Pazopanib
2036 PR Kidney, adrenal, lungs Temsirolimus
2041 PR Liver, tongue Cediranib
2042 PR Liver, lung Sunitinib
2045 PR LNs, liver High-dose IL-2
2046 PR Pancreas, lung, LNs, bone, peritoneum Temsirolimus
  1. Abbreviations: IL-2, interleukin-2; PR, partial response; LNs, lymph nodes.